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Background  and  purpose     Although  total  elbow  arthroplasty 
(TEA) is a recognized procedure for the treatment of the painful 
arthritic elbow, the choice of implant is still obscure. We evaluated 
the survival of different TEA designs and factors associated with 
survival using data from a nationwide arthroplasty register. 
Methods   1,457 primary TEAs for rheumatoid elbow destruc-
tion were performed during 1982 to 2006 in one hospital special-
ized in the treatment of rheumatoid arthritis (n = 776) and in 
19 other hospitals (n = 681). The mean age of the patients was 
59 years and 87% of the TEAs were performed in women. We 
selected different contemporary TEA designs, each used in more 
than 40 operations including the Souter-Strathclyde (n = 912), 
i.B.P./Kudo (n = 218), Coonrad-Morrey (n = 164), and NESim-
plavit/Norway (n = 63) to assess their individual survival rates. 
Kaplan-Meier analysis and the Cox regression model were used 
for survival analysis.
Results   The most frequent reason for revision was aseptic loos-
ening (47%). We found no differences in survival rates between 
different TEA designs. We did, however, find a 1.5-fold (95% CI: 
1.1–2.1)  elevated  risk  of  revision  in  unspecialized  hospitals  as 
compared to the one hospital specialized in treatment of rheu-
matoid arthritis. In the Souter-Strathclyde subgroup, there was 
a reduced risk of revision (RR 0.6, p = 0.001) in TEAs implanted 
over 1994–2006 as compared to those implanted earlier (1982–
1993). The 10-year survivorship for the whole TEA cohort was 
83% (95% CI: 81–86), which agrees with earlier reports. 
Interpretation   The influence of implant choice on the survival 
of TEA is minor compared to hip and knee arthroplasties. Inferior 
survival rates of the TEAs performed in the unspecialized hospi-
tals demonstrates the importance of proper indications, surgical 
technique, and postoperative follow-up, and endorses the need for 
centralization of these operations at specialized units. 

 
The elbow is involved in two-thirds of all patients with rheu-
matoid arthritis (RA), and, in joints with severe destruction, 
total elbow arthroplasty (TEA) is often indicated (Scott et al. 
1986, Hämäläinen et al. 1991, Lehtinen et al. 2001). There 
are several unlinked and linked TEA designs currently avail-
able  with  radically  different  geometries  (King  et  al.  1993, 
Kamineni et al. 2005). TEA is, however, much less common 
than hip or knee replacement; it has an annual incidence of 
1 per 100,000 inhabitants (Rahme et al. 2001) and compre-
hensive assessment of different concepts and models is thus 
difficult in comparative randomized studies.
Recent  studies  have  indicated  that  observational  reviews 
may give results that are similar to those of randomized trials 
(Benson and Hartz 2000, Concato et al. 2000). However, any 
generalization of results from such observational studies must 
be made with caution, since TEA is a relatively specialized 
orthopedic  procedure  and  is  frequently  performed  by  only 
a few individuals. The monitoring of arthroplasty by means 
of  long-established  nationwide  arthroplasty  registers  has 
improved the quality of hip replacement (Herberts and Mal-
chau 2000); these registers have proved to be valuable tools 
in  the  evaluation  of  concepts  in  joint  replacement  surgery 
(Eskelinen  et  al.  2005). The  Finnish Arthroplasty  Register 
was established in 1980, and data from hip, knee, shoulder, 
and elbow replacements have been continuously recorded for 
more than 25 years (Paavolainen et al. 1991). 
The present study was initiated in order to examine—at a 
nationwide level—the survival of different TEA designs and 
the factors affecting survival in patients with RA, by using the 
data from the Finnish Arthroplasty Register.
Patients and methods
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ish Arthroplasty Register (Puolakka et al. 2001) relating to 
patients who underwent TEA between 1982 and 2006. The 
register contains data on 1,612 primary TEAs, each of which 
was recorded individually for every operation since the start 
of the register. Of these 1,612 TEAs, 1,457 (90%) were per-
formed due to RA and these were selected for further analysis. 
The coverage of the Finnish Arthroplasty Register was ana-
lyzed in 1994–1995 by comparing its data with those of the 
discharge registers of the participating hospitals; it was found 
to cover 90% of implantations and implant removals. Since 
1995, every few years the data in the register have been com-
pared with those in the hospital discharge registers. Currently, 
over 95% of implantations are recorded. An English transla-
tion of the form used for data collection has been published 
elsewhere (Paavolainen et al. 1991). Revisions were linked to 
the primary operation using the unique personal identification 
number assigned to each resident of Finland.
Hospital-specific trends
In Finland, the majority of the 1,457 TEAs for RA have been 
performed in a foundation-based hospital specialized in the 
treatment of RA (Table 1). Nineteen other hospitals have also 
performed TEAs for RA. We analyzed the overall survival of 
TEAs performed in a specialized hospital and compared it to 
the unspecialized hospitals group in order to assess the effect 
of hospital volume. This comparison was only performed for 
the Souter-Strathclyde subgroup, as only 27 TEAs had been 
performed in the specialized hospital with other designs of 
total elbow replacement (Table 1).
Implant-specific trends
Inclusion criteria In order to assess the survival of different 
TEA designs, we selected only those designs that had been 
used in more than 40 operations during the study period (Hav-
elin et al. 1995). In addition, only implants with a mean follow-
up of more than 3 years, and with more than 20 patients at risk 
at five years, were included. We included bilateral TEAs as 
separate cases in the analysis since bias by this procedure is 
likely to be negligible (Robertsson and Ranstam 2003).
Types of prostheses selected
To meet our inclusion criteria, the following implants were 
selected:  NESimplavit  (Implantcast,  Buxtehude,  Germany), 
formerly Norway elbow (3M, St. Paul, MN); Kudo and i.B.P. 
(Biomet, Warsaw, IN), Souter-Strathclyde (Stryker, Kalama-
zoo, MI), and Coonrad-Morrey (Zimmer, Warsaw, IN) (Table 
2). All the Souter-Strathclyde models (short and long-stemmed 
humeral components and metal-backed and all-polyethylene 
ulnar components) were considered as one group. Since this 
prosthesis has been used in 2 out of 3 of all TEAs performed 
in Finland, it was used as the reference design for purposes 
of comparison. The NESimplavit is a new brand name that 
formerly went under the name of Norway elbow prosthesis. 
These are identical in design, which allowed us to pool the 
data. All the implanted Kudo prostheses were of the latest gen-
eration, the i.B.P. being the latest modified version. In order to 
be able to compare the results of these unconstrained resurfac-
ing models with other designs, the data from these two models 
were also pooled. All of the Coonrad-Morrey models were also 
considered as one, even though small adjustments have been 
made to the metal composition, surface coating, and locking 
pin. Time-dependent trends were also analyzed for all implants 
and for the Souter-Strathclyde prosthesis alone. Of the con-
temporary implant designs, only the Discovery elbow (Biomet) 
was excluded due to an insufficient number of operations.
Statistics
The  endpoint  for  survival  was  defined  as  revision  involv-
Table  1.  Trends  in  total  elbow  arthroplasty  (TEA)  for  rheumatoid 
arthritis in one hospital specialized in the treatment of rheumatoid 
arthritis and in 19 other hospitals in Finland during 1982–2006
  Specialized hospital   Other hospitals
Mean follow-up (SD)   6.3 (4.3)   8.8 (5.0)
Total number of TEAs   776   681
TEAs during 1982–1993   295   102
TEAs during 1994–2006   460   578
NESimplant/Norway   27   36
Coonrad-Morrey   0   164
i.B.P./Kudo   0   218
Souter-Strathclyde   712   200
Table 2. Different prosthesis designs used in total elbow arthroplasty for rheumatoid arthritis from 1982 through 2006
Implant   n   Concept   Mean    Women    Implantation    Number     Operations  
      age    period  of  per hospital 
            hospitals  (range)
NESimplant/Norway   63   Unconstrained, humero-ulnar relationship  realigned   60   86%   1997–2006   4   11 (4–15)
Coonrad-Morrey   164   Linked, semicontrained “sloppy” hinge   63   92%   1995–2006   14   10 (1–58)
i.B.P./Kudo   218   Unconstrained, anatomic humero-ulnar relationship    60   79%   1994–2006   13   16 (1–56)
Souter-Strathclyde   912   Unconstrained, humero-ulnar  relationship realigned  58   87%   1982–2006   12   75 (1–697) a
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ing either one component or the whole implant (removal or 
exchange). Kaplan-Meier survival data were used to construct 
the survival probabilities of implants at 4, 7, 10, and 15 years. 
Survival  data  obtained  in  the  Kaplan-Meier  analysis  were 
compared by the log-rank test. The Cox multiple-regression 
model was used to study differences between groups and to 
adjust for potential confounding factors. In all models, the 
confounding factors were age and gender. The factors studied 
with the Cox model were as follows: TEA designs, hospital 
type (specialized hospital vs. all other hospitals), and implan-
tation period. All models included adjustment for differences 
in age and gender.
Survivorships  of  the  other  TEA  designs  were  compared 
with that of the Souter-Strathclyde TEA (reference design). 
As the Souter-Strathclyde was the only design that had been 
used over 1982–1993 (Table 2), the effect of the implantation 
period (cohort effect analysis; see Eskelinen et al. 2005) was 
only analyzed in the Souter-Strathclyde subgroup and for 2 
time periods: 1982–1993 and 1994–2006. In order to mini-
mize the effects of the confounding factors, time period analy-
sis was also adjusted for hospital type. The Cox regression 
analyses provided estimates of survival probabilities and revi-
sion risk ratios (RRs) for different factors. Estimates from the 
Cox analyses were used to construct adjusted survival curves 
at mean values of the risk factors. The Wald test was used 
to calculate p-values for data obtained from the Cox multiple 
regression analysis. Differences between groups were consid-
ered statistically significant if the p-values were less than 0.05 
in a two-tailed test. We used SPSS statistical software version 
14.0.
Results
Patient characteristics
Of the 1,457 TEA operations, 1,262 (87%) were performed 
in women patients. At the time of the operation, the mean age 
of the patients was 59 (18–89) years. 793 (54%) of all the 
TEAs were performed on the right elbow. The mean annual 
insidence of TEA was 1.3 per 100,000 inhabitants.
Implants
Over the whole study period, 9 different TEA designs were 
used, 6 of them in 4 groups with more than 40 operations 
(Table 3). All implants were cemented. At the end of the study 
period (2005–2006), 6 TEA designs were still in use in Fin-
land. Of the models still being used, only the Discovery elbow 
(Biomet) was excluded due to an insufficient number of opera-
tions. Epidemiological data relating to the designs analyzed 
are given in Table 2.
Hospital-specific trends
In the Souter-Strathclyde subgroup, the Cox regression model 
(adjusted for age and sex) showed a 1.5-fold (95% CI: 1.1–2.2) 
increased risk of revision for the non-specialized hospitals as 
compared to the specialized hospital (p = 0.02) (Figure 1).
Survival of TEA designs
We found no differences in survival rates between different 
TEA designs over the whole study period, using either the 
Kaplan-Meier analysis or the Cox regression model (with or 
without adjustment for age and sex) (Table 4 and Figure 2).
Cohort effect analysis
In the Cox regression analysis of the Souter-Strathclyde sub-
group, there was a significantly reduced risk of revision (RR 
0.6; 95% CI: 0.4–0.8) in TEAs implanted in 1994–2006 as 
Table 3. Implants used for total elbow arthroplasty in rheumatoid 
arthritis in Finland from 1982 through 2006 and their inclusion in 
the study
Brand of implant   n   Inclusion  Used during 
    in analysis   years
Souter-Strathclyde   912   Yes   1982–2006
Kudo   175   Yes   1994–2003
Coonrad-Morrey   164   Yes   1995–2006
i.B.P.   43   Yes   2001–2006
Norway   13   Yes   1997–1998
Pritchard-Walker Mark II   20   No   1987–1998
NESimplant   50   Yes   2003–2006
Discovery   52   No   2003–2006
Other   1   No   1982
Total   1,345  
Figure  1.  Cox-adjusted  cumulative  survival  of TEAs  for  rheumatoid 
arthritis  in  one  hospital  specialized  in  the  treatment  of  rheumatoid 
arthritis (n = 776) and in 19 other hospitals (n = 681) in Finland from 
1982  through  2006. The  endpoint  was  defined  as  revision  for  any 
reason. Adjustment was made for age, sex, and prosthesis design.
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compared  to  those  implanted  earlier,  i.e.  1982–1993  (p  = 
0.001) (Figure 3).
Effect of age and sex on survivorship
Age and sex did not have any statistically significant effect on 
survivorship in the Cox multiple regression model (unadjusted 
and adjusted for implant design)—either when all TEAs were 
analyzed or when analyzing the subgroup of patients treated 
with the Souter-Strathclyde total elbow replacement.
Revision operations
During the period 1982–2006, 201 revisions were reported. 
Thus, the 10-year survivorship for the whole TEA cohort was 
83% (95% CI: 81–86). The most common reason for revision 
was aseptic loosening (47%, n = 95). This was followed by 
prosthesis dislocation (16%, n = 32), periprosthetic fracture 
(14%, n = 29), infection (12%, n = 25), fracture of the pros-
thesis (4%, n = 9), and malalignment of the prosthesis (1%, n 
= 2). Other, miscellaneous reasons (including exchange of the 
liner) accounted for 4% of the revisions (n = 9).
Discussion
To the best of our knowledge, there have been no previous 
reports on results of TEA conducted at a nationwide level. 
The  mean  annual  incidence  of TEA  was  1.3  per  100,000. 
We found no differences in survival between different TEA 
Table 4. Cox-adjusted survival of different total elbow replacement designs used in patients with rheumatoid arthritis from 1982 through 
2006 in Finland
  A  B  C  D  E  F  G  H  I  J  K  L  M
NES/Norway   63   3.5 (0–10)   29   92 (85–100)   0  –  0  –  0  –  1.1 (0.4–2.7)  0.9
Coonrad-Morrey   164   4.6 (0–10)   108   96 (92–99)   36   89 (83–96)   3  –  0  –  0.7 (0.3–1.3)   0.2
i.B.P./Kudo   218   6.5 (0–13)   173   93 (90–97)   110   89 (84–94)   46   83 (76–90)   0  –  0.9 (0.3–1.3)   0.5
Souter-Strathclyde   912  8.8 (0–25)   771   93 (91–94)   612   88 (86–90)   419   82 (80–85)   97   75 (70–79)   1.0  –
A  Brand of implant  
B  n  
C Mean follow (range), years  
D Number of elbows at risk at 4 years  
E  4-year survival (95% CI), percent 
F  Number of elbows at risk at 7 years  
G 7-year survival (95% CI), percent 
H Number of elbows at risk at 10 years  
I  10-year survival (95% CI), percent
J  Number of elbows at risk at 15 years  
K  15-year survival (95% CI), percent
L  Adjusted RR for revision (95% CI) from the Cox regression 
analysis (other TEA designs compared to the Souter-Strathclyde 
prosthesis; adjustment was made for age and sex). 
M p-value
Figure  2.  Cox-adjusted  cumulative  survival  of  different  prosthesis 
designs  used  in TEA  for  rheumatoid  arthritis  in  Finland  from  1982 
through 2006. The endpoint was defined as revision for any reason. 
Adjustment was made for age and sex.
Figure 3. Cox-adjusted cumulative survival of the Souter-Strathclyde 
total elbow replacements used for rheumatoid arthritis in Finland over 
2 different time periods. Adjustment was made for age, sex, and type 
of hospital.
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designs or concepts, based on the data recorded in the Finn-
ish Arthroplasty Register. The most significant finding in our 
study was the better TEA survival when performed in a hospi-
tal that specialized in the treatment of rheumatoid arthritis.
We are aware that the current register-based study had cer-
tain limitations. For example, we were not able to report any 
subjective  outcome  measurements,  e.g.  Mayo  Elbow  Per-
formance Score or disease-specific quality of life measure-
ments. Moreover, it is not possible to conduct radiographic 
analyses in the large number of register-based patients. Fur-
thermore, when rheumatoid patients are involved, a register-
based study may have the pitfall that some of the patients 
diagnosed as having RA may actually be affected by juvenile 
arthritis or other subtypes of chronic arthritis. Little is known 
about TEA in different subtypes of chronic arthritis (Connor 
et al 1998). 
The primary indication for TEA is a painful arthritic elbow 
with Larsen grade-IV or grade-V (Larsen et al. 1977) rheu-
matic destruction (Scott et al. 1986, Hämäläinen et al. 1991, 
Little  et  al.  2005a). There  are  only  limited  published  data 
to guide a surgeon in implant selection. A recent systematic 
review of the English-language literature (Little et al. 2005a) 
found that a high proportion of the published studies on TEA 
had originated from the establishments of the designers of the 
implants. In addition, no recognized form of survival analysis 
such as the Kaplan-Meier technique had usually been used in 
these studies. In their attempt to re-calculate the revision rates 
for different TEA designs in patients with RA, Little et al. 
found an overall revision rate of 13% at 5 years. Our register-
based study has revealed a similar rate of prosthesis survival, 
with 88–89% of patients revision-free at 7 years.
Traditionally, the TEA designs have been divided into 3 cat-
egories: fully constrained rigid-hinge design, semi-constrained 
hinge design, and unconstrained unlinked design. Fully con-
strained designs have a lack of flexibility in the coronal plane 
and in rotation, resulting in high shear stresses and early loos-
ening rates, and these model are no longer in use (Garrett et 
al. 1977, Amis et al. 1981). Unconstrained models rely on 
sufficient bone stock and an intact soft tissue sleeve, whereas 
the semi-constrained designs can be used in an elbow that is 
unstable because of bone or soft tissue deficiency (Wright 
et al. 2000). There are, however, reports of favorable results 
after TEA with the use of the unconstrained Souter-Strath-
clyde implant for the severest forms of rheumatic destruction 
and substantial bone loss (Ikävalko et al. 2004). On the other 
hand, Kamineni and colleagues (2005) found large variation 
in intrinsic constraint of unlinked TEA designs. Thus, it may 
not be practical to consider all unlinked prostheses as a group. 
In their review article, Little and colleagues (2005a) found no 
differences in survival between different prostheses or con-
cepts. In the studies comparing contemporary TEA designs, 
it has not been possible to demonstrate the superiority of one 
model or concept over another (Connor et al. 1998, Wright et 
al. 2000, Little et al. 2005b).
In the present study, we pooled the results of the Kudo pros-
thesis and its latest version (i.B.P.), and we also pooled the 
data for the NESimplavit and its former brand, the Norway 
prosthesis. In spite of this, we could not find statistically sig-
nificant  differences  between  survival  rates  of  the  different 
designs. In their comparative study of 3 implants using any 
revision as the endpoint, Little and coworkers (2005b) found 
the 5-year survival rates of the Souter-Strathclyde, Kudo, and 
Coonrad-Morrey implants to be 85%, 93%, and 90%. The dif-
ferences were not statistically significant, however. Our sur-
vival rates (Table 3) are in line with their findings.
Several studies have found an association between the hos-
pital volume and adverse events in the context of total hip 
arthroplasty (THA), but no such studies on TEA have been 
published. Both surgeon volume and hospital volume have 
been suggested to be the best indicators of orthopedic adverse 
events in patients undergoing THA (Solomon et al. 2002). In a 
systematic literature review, an association was found between 
higher hospital volumes and lower rates of mortality and hip 
dislocation (Shervin et al. 2007). Inferior survival rates of the 
TEAs performed in the unpecialized hospitals demonstrate 
the importance of proper indications, surgical technique, and 
postoperative  follow-up,  and  endorse  the  centralization  of 
these operations at specialized units.
The inferior survival rates in the Souter-Strathclyde TEAs 
implanted  in  the  early  years  of  the  Finnish  Arthroplasty 
Register have improved over the years. Possible reasons for 
this  include  better  surgical  technique  with  triceps-sparing 
approaches, better cementing technique and equipment, and a 
postoperative regime that allows the triceps to heal. Also, it is 
possible that the elbows that underwent earlier operations may 
have undergone more severe destruction from RA, and were 
thus less optimal for implant arthroplasty.
 According to our results, it appears that success of recon-
struction of a non-weight bearing joint such as the elbow by 
means of TEA is not as affected by implant choice to the same 
extent as hip (Eskelinen et al. 2005) and knee (Robertsson et 
al. 2001) arthroplasty. The explanation for this may be that 
both the contemporary semi-constrained and unconstrained 
TEA designs perform in a more or less unconstrained manner 
when properly inserted (Hargreaves and Emery 1999).
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